Open Clinical Trials

Below is a list of open clinical trials. Please talk to your doctor if you are interested in participating in our research program.

  1. Alliance A032103 “MODERN” : Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study 

https://clinicaltrials.gov/study/NCT05987241

  1. Alliance A011801: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial 

https://clinicaltrials.gov/study/NCT04457596

  1. Alliance A012103: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab 

https://clinicaltrials.gov/study/NCT05812807

  1. CAMBRIA-1/ AstraZeneca/ D8531C00002: A Study of Camizestrant in ER+/​HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) 

https://clinicaltrials.gov/study/NCT05774951

  1. CAMBRIA-2 / AFT-66 / AstraZeneca D8535C00001: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/​HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2) 

https://clinicaltrials.gov/study/NCT05952557?term=d8535C00001&rank=1

  1. CCTG MA39: Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT) 

https://www.clinicaltrials.gov/study/NCT03488693

  1. DFCI 21-159 “ATEMPT 2.0”: ATEMPT 2.0: Adjuvant T-DM1 Vs TH 

https://clinicaltrials.gov/study/NCT04893109

  1. NRG BR007 “DEBRA”: De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA) 

https://clinicaltrials.gov/study/NCT04852887?term=br007&rank=2

  1. NRG BR009 “OFSET”: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/​HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) 

https://clinicaltrials.gov/study/NCT05879926?term=NCT05879926&rank=1

  1. SWOG S1703: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer 

https://www.clinicaltrials.gov/study/NCT03723928

  1. SWOG S2007: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases 

https://clinicaltrials.gov/study/NCT04647916

  1. NRG GI008 “CIRCULATE-US”: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) 

https://clinicaltrials.gov/study/NCT05174169

  1. SWOG “LUNGMAP”: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer 

https://www.clinicaltrials.gov/study/NCT03851445

S1900G: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) 

https://clinicaltrials.gov/study/NCT05642572

S1900J: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) 

https://clinicaltrials.gov/study/NCT06116682

S1900K: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) 

https://clinicaltrials.gov/study/NCT06031688

  1. AFT-57: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC 

https://clinicaltrials.gov/study/NCT05798663

  1. A081801: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial 

https://clinicaltrials.gov/study/NCT04267848

  1. Alliance A212102: Collecting Blood Samples from Patients with and Without Cancer to Evaluate Tests for Early Cancer Detection 

https://www.clinicaltrials.gov/study/NCT05334069

  1. ECOG-ACRIN EA8184: To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring 

https://clinicaltrials.gov/study/NCT04597359?term=NCT04597359&rank=1

  1. NRG GU008: Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer 

https://clinicaltrials.gov/study/NCT04134260

  1. NRG GU009 “PREDICT-RT”: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial 

https://clinicaltrials.gov/study/NCT04513717

  1. NRG GU010 “GUIDANCE”: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score 

https://clinicaltrials.gov/study/NCT05050084

  1. SWOG S1802: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer 

https://www.clinicaltrials.gov/study/NCT03678025

  1. Alliance A022104: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS) 

https://clinicaltrials.gov/study/NCT05610163

  1. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) 

https://clinicaltrials.gov/study/NCT02693535